Related Experiment Video
Updated: Sep 3, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice
G Leto1, F M Tumminello, N Gebbia
1Institute of Pharmacology, Faculty of Medicine, University of Palermo, Italy.
Abstract:
The antimetastatic activity of adriamycin in combination with proteinase inhibitors was investigated in mice bearing the metastatic tumors L1210 leukemia, Lewis lung carcinoma or M5076 sarcoma. Leupeptin, a cathepsin B inhibitor, when administered as a single agent was devoid of antimetastatic activity but some therapeutic activity was noted in mice with Lewis lung carcinoma when the agent was administered in combination with adriamycin. Pepstatin A, a cathepsin D inhibitor, had no effect as a single agent in mice with L1210 leukemia but displayed some antimetastatic activity in mice with Lewis lung carcinoma. In mice with M5076 sarcoma the combination of pepstatin A and adriamycin resulted in antimetastatic activity significantly greater than that observed with each agent alone. These results suggest that combinations of proteinase inhibitors with antitumor drugs such as adriamycin, might result in more effective antimetastatic treatment.
Insights
Combining adriamycin with proteinase inhibitors shows promise for treating metastatic cancers. Certain combinations demonstrated significant antimetastatic activity in preclinical models, suggesting a potential new therapeutic strategy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Metastasis Research
Background:
- Metastatic tumors pose a significant challenge in cancer treatment.
- Adriamycin is a common chemotherapeutic agent.
- Proteinase inhibitors are being explored for their potential role in cancer therapy.
Purpose of the Study:
- To investigate the antimetastatic activity of adriamycin in combination with specific proteinase inhibitors.
- To evaluate the efficacy of leupeptin (cathepsin B inhibitor) and pepstatin A (cathepsin D inhibitor) in combination with adriamycin against metastatic tumors in mice.
Main Methods:
- The study utilized mouse models bearing metastatic L1210 leukemia, Lewis lung carcinoma, and M5076 sarcoma.
- Adriamycin was administered in combination with leupeptin or pepstatin A.
- Antimetastatic and therapeutic activities were assessed.
Main Results:
- Leupeptin showed some therapeutic activity with adriamycin in Lewis lung carcinoma.
- Pepstatin A demonstrated antimetastatic activity in Lewis lung carcinoma and significantly enhanced adriamycin's antimetastatic effect in M5076 sarcoma.
- Neither inhibitor was effective alone against L1210 leukemia.
Conclusions:
- Combinations of proteinase inhibitors with adriamycin exhibit potential antimetastatic effects.
- Specific proteinase inhibitors may enhance the efficacy of conventional chemotherapy against certain metastatic cancers.
- Further research into combined therapies could lead to improved antimetastatic treatment strategies.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 20, 2019